ENTITY

Forty Seven Inc (FTSV US)

4
Analysis
Health CareUnited States
Forty Seven, Inc. operates as a clinical-stage immuno-oncology company. The Company develops novel checkpoint therapies to activate macrophages targeting cancer immune evasion pathways. Forty Seven serves customers in the State of California.
more
bullishI-Mab
29 Mar 2021 09:05

I-Mab (IMAB US) - Insights On Core Products TJC4, TJ202 and TJ101

As I-MAB has come to a key phase from R&D to commercialization, this article analyzed both the strength and the concerns for its core products...

Logo
221 Views
Share
18 Feb 2021 09:54

Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma

This article mainly analyzed Innovent in terms of its current listed products (Sintilimab, Bevacizumab, Adalimumab and Rituximab), its pipeline,...

Logo
401 Views
Share
22 Nov 2019 11:27

Overweight Global Technology & Industrials

In this report we highlight attractive and actionable themes within developed int’l markets: Technology and Industrials continue to be two of the...

Logo
418 Views
Share
bullishS&P 500 INDEX
22 May 2019 05:14

U.S. Equity Strategy: Neutral Outlook; Opportunities Within Staples and Utilities

In last week’s Compass (5/14) we laid our case for a more cautious outlook as a result of several negative developments, including breakdowns for...

Logo
491 Views
Share
No more insights
x